4.7 Article

A preclinical xenograft model of prostate cancer using human tumors

期刊

NATURE PROTOCOLS
卷 8, 期 5, 页码 836-848

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/nprot.2013.043

关键词

-

资金

  1. Australian National Health and Medical Research Council [1035721, 606492, 614296]
  2. Prostate Cancer Foundation of Australia
  3. Victorian Cancer Agency (CAPTIV)
  4. Peter and Lyndy White Foundation
  5. Yorkshire Cancer Research Programme Support
  6. Medical Research Council [G0900871] Funding Source: researchfish
  7. MRC [G0900871] Funding Source: UKRI

向作者/读者索取更多资源

Most cases of prostate cancer are now diagnosed as moderate-grade localized disease. These tumor specimens are important tools in the discovery and translation of prostate cancer research; however, unlike more advanced tumors, they are notoriously difficult to grow in the laboratory. We developed a system for efficiently xenografting localized human prostate cancer tissue, and we adapted this protocol to study the interactions between the specific subsets of epithelial and stromal cells. Fresh prostate tissues or isolated epithelial cells are recombined with mouse seminal vesicle mesenchyme (SVM) and grafted under the renal capsule of immunodeficient mice for optimum growth and survival. Alternatively, mouse mesenchyme can be replaced with human prostate fibroblasts in order to determine their contribution to tumor progression. Grafts can be grown for several months to determine the effectiveness of novel therapeutic compounds when administered to host mice, thereby paving the way for personalizing the treatment of individual prostate cancers.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据